90.77
90.77 (0%)
As of Feb 14, 2025
Praxis Precision Medicines, Inc. [PRAX]
Source:
Company Overview
Praxis Precision Medicines, Inc is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal excitation-inhibition imbalance.
| Country | United States |
| Headquarters | boston, massachusetts |
| Phone Number | 617-300-8460 |
| Industry | manufacturing |
| CEO | Marcio Souza |
| Website | www.clinicaltrials.gov |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $8.6 |
| Operating Profit | $-200.2 |
| Net Income | $-182.8 |
| Net Cash | $134.1 |
Profit Ratios
| Gross Margin | $8.6 |
| Operating Margin | -2,340.3 |
| Profit as % of Revenues | -4.7% |
| Profit as % of Assets | -64% |
| Profit as % of Stockholder Equity | -41% |
Management Effectiveness
| Return on Equity | -41% |
| Return on Assets | -37.8% |
| Turnover Ratio | 3% |
| EBITA | $-200.2 |
Balance Sheet and Cash Flow Measures
| Total Assets | $483.1 |
| Total Liabilities | $37.7 |
| Operating Cash Flow | $-131.8 |
| Investing Cash Flow | $-248.5 |
| Financing Cash Flow | $514.3 |
